From owner-watcher-work@jp.FreeBSD.org Fri Nov  2 13:27:41 2012
Received: (from daemon@localhost)
	by castle.jp.FreeBSD.org (8.11.6p2+3.4W/8.11.3) id qA24Rff10710;
	Fri, 2 Nov 2012 13:27:41 +0900 (JST)
	(envelope-from owner-watcher-work@jp.FreeBSD.org)
Received: from YAQGGKT ([117.6.224.170])
	by castle.jp.FreeBSD.org (8.11.6p2+3.4W/8.11.3) with ESMTP/inet id qA24Rdu10702;
	Fri, 2 Nov 2012 13:27:40 +0900 (JST)
	(envelope-from chopsk20@royalbankamerica.com)
Received: from [117.6.224.170] (port=1678 helo=P1MAY30)
	by mx.usa.net with asmtp 
	id 819B4A-0009E0-65
	for <usita@jp.freebsd.org>; Thu, 1 Nov 2012 20:27:30 -0800
Message-ID: <9BD14042358C42739F5CB7706F9A437D@P1MAY30>
From: "Gil Bernard" <chopsk20@royalbankamerica.com>
To: <usita@jp.FreeBSD.org>
MIME-Version: 1.0
Content-Type: text/plain;
	format=flowed;
	charset="iso-8859-1";
	reply-type=original
Content-Transfer-Encoding: 7bit
X-Priority: 3
X-MSMail-Priority: Normal
X-Mailer: Microsoft Windows Mail 6.0.6001.18000
X-MimeOLE: Produced By Microsoft MimeOLE V6.0.6001.18049
X-Mras: Ok
Reply-To: watcher-work@jp.FreeBSD.org
Precedence: list
Date: Thu, 1 Nov 2012 20:27:30 -0800
X-Sequence: watcher-work 15863
Subject: [watcher-work 15863] Entering A Potential $ 80bil Cancer Drugs Market 
Sender: owner-watcher-work@jp.FreeBSD.org
X-Originator: chopsk20@royalbankamerica.com
X-Distribute: distribute version 2.1 (Alpha) patchlevel 24e+060209

A pioneering US biotech company developing pharmaceutical cannabis products, is pleased to issue Sales Guidance and Outlook. Sales for 2012 are forecasted to be $6,846,000 and has the potential to increase to $ 65,740,000 in 2014. 

This sales forecast translates into positive earnings of $ .02 per share earnings for 2014. The Company is dedicated to working with Federal, State, and Local regulatory agencies, as well as similar agencies in other countries such as Health Canada, and other international regulatory bodies. 

The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance.

Attnt. to MedicalandHealthCareInvestors
Wearelookingforleadingmedicalandhealthcareinvestorstohelpprovideexcellentandefficientmedicalandhealthcareforourfutureresearches.Ifyoubelieveyoucanmakeadifferenceinpeopleslives,wewelcomeyoutocontactusformoreinformation. 


Formoreinformation,pleasevisit www.xn----gtblj0ar.xn--p1ai

You can unsubscribe from all our future email communications at www.opt-out-me.com
